Alyssa Wyant
About Alyssa Wyant
Alyssa Wyant is the Chief Regulatory & Quality Officer with over 20 years of experience in regulatory affairs, specializing in CNS and rare diseases.
Title
Alyssa Wyant currently holds the position of Chief Regulatory & Quality Officer. She has held this role since November 2021, after a tenure as Senior Vice President of Regulatory and Quality from September 2020 to November 2021.
Previous Roles
Alyssa Wyant served as Senior Vice President of Regulatory Affairs at EryDel S.p.A from January 2019 to August 2020. Before that, she held senior leadership roles at Edge Therapeutics, Inc. and PTC Therapeutics, Inc.
Experience in Regulatory Affairs
With over 20 years of experience in regulatory affairs, Alyssa Wyant has led the creation and implementation of global strategies for the development, registration, and post-approval activities for numerous approved products. Her work spans across CNS and rare diseases, ensuring compliance and guiding successful product launches and post-market support.
Education and Expertise
Alyssa Wyant holds a Bachelor of Science degree in cell and molecular biology from the University of Washington. Her academic background in molecular biology supports her extensive professional experience in regulatory and quality roles.